Communiqués ARS Pharmaceuticals, Inc.

Actions

SPRY

US82835W1080

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 04/08/2026			Varia. 5j.	Varia. 1 janv.
5,320 ^USD	-2,56%		-6,17%	-54,33%

17/07	Ars Pharmaceuticals, Inc. annonce des changements au sein de sa direction, effectifs au 15 juillet 2026	CI
07/07	ARS Pharmaceuticals, Inc. annonce la nomination de Donn Casale au poste d'administrateur, à compter du 7 juillet 2026	CI

Communiqués

03/08	ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results	GL
07/07	ARS Pharmaceuticals Announces CEO Succession	GL
01/07	SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud	BU
24/06	ARS Pharmaceuticals Provides Commercial and Financial Updates	GL
04/06	Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies	GL
15/05	ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update	GL
13/05	ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President	GL
07/05	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results	GL
15/04	Neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)	GL
30/03	ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg Label	AQ
27/03	ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label	GL
09/03	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization	GL
23/02	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences	GL
23/02	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences	AQ
10/02	ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting	GL
02/02	EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg	GL
02/02	EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg	AQ
22/01	ARS Pharmaceuticals, Inc. - California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use	AQ
21/01	California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use	GL
30/12	ARS Pharmaceuticals - neffy Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions	AQ
29/12	Neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)	GL
26/11	ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference	GL
10/11	ARS Pharmaceuticals : Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)	PU
10/11	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)	GL
04/11	ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)	GL